Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NASDAQ:BBNX NYSE:BFLY NASDAQ:LMAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$44.84$40.43$9.35▼$45.83$2.38B1.121.12 million shs1.30 million shsBBNXBeta Bionics$13.88$11.71$8.80▼$32.71$618.52M3.4936,978 shs1.24 million shsBFLYButterfly Network$8.85-0.6%$4.93$1.32▼$8.94$2.27B2.227.43 million shs60.04 million shsLMATLeMaitre Vascular$93.95$102.42$79.00▼$118.01$2.15B0.54304,121 shs724,887 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen0.00%+4.28%+8.55%+45.68%+382.67%BBNXBeta Bionics0.00%-4.47%+30.82%+29.42%-21.93%BFLYButterfly Network0.00%+59.91%+97.35%+123.23%+308.82%LMATLeMaitre Vascular0.00%+2.16%-5.60%-11.63%+15.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$44.84$40.43$9.35▼$45.83$2.38B1.121.12 million shs1.30 million shsBBNXBeta Bionics$13.88$11.71$8.80▼$32.71$618.52M3.4936,978 shs1.24 million shsBFLYButterfly Network$8.85-0.6%$4.93$1.32▼$8.94$2.27B2.227.43 million shs60.04 million shsLMATLeMaitre Vascular$93.95$102.42$79.00▼$118.01$2.15B0.54304,121 shs724,887 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen0.00%+4.28%+8.55%+45.68%+382.67%BBNXBeta Bionics0.00%-4.47%+30.82%+29.42%-21.93%BFLYButterfly Network0.00%+59.91%+97.35%+123.23%+308.82%LMATLeMaitre Vascular0.00%+2.16%-5.60%-11.63%+15.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 2.73Moderate Buy$46.503.70% UpsideBBNXBeta Bionics 2.64Moderate Buy$19.7041.93% UpsideBFLYButterfly Network 2.33Hold$5.56-37.15% DownsideLMATLeMaitre Vascular 2.75Moderate Buy$112.6019.85% UpsideCurrent Analyst Ratings BreakdownLatest BBNX, AXGN, BFLY, and LMAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026LMATLeMaitre Vascular Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$120.005/29/2026AXGNAxoGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/29/2026AXGNAxoGen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/27/2026BBNXBeta Bionics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$19.00 ➝ $17.005/20/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/18/2026BBNXBeta Bionics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$23.00 ➝ $11.005/6/2026BFLYButterfly Network Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/6/2026LMATLeMaitre Vascular Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/6/2026LMATLeMaitre Vascular Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$105.00 ➝ $120.005/6/2026LMATLeMaitre Vascular Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$118.00 ➝ $127.005/6/2026LMATLeMaitre Vascular Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$94.00 ➝ $104.00(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$225.21M10.59N/AN/A$2.79 per share16.07BBNXBeta Bionics$100.25M6.17N/AN/A$6.53 per share2.13BFLYButterfly Network$97.61M23.09N/AN/A$0.77 per share11.49LMATLeMaitre Vascular$249.60M8.60$2.90 per share32.37$17.35 per share5.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$15.70M-$0.64N/A166.07N/A-13.21%-9.63%-6.26%8/4/2026 (Estimated)BBNXBeta Bionics-$73.20M-$1.51N/AN/AN/A-60.27%-23.00%-20.55%N/ABFLYButterfly Network-$77.06M-$0.30N/AN/AN/A-73.63%-34.41%-23.91%7/31/2026 (Estimated)LMATLeMaitre Vascular$57.73M$2.7134.6728.732.6124.35%15.36%9.78%8/4/2026 (Estimated)Latest BBNX, AXGN, BFLY, and LMAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026LMATLeMaitre Vascular$0.66$0.68+$0.02$0.68$66.67 million$66.55 million4/30/2026Q1 2026BFLYButterfly Network-$0.04-$0.03+$0.01-$0.05$26.08 million$26.53 million4/28/2026Q1 2026AXGNAxoGen$0.12$0.07-$0.05-$0.38$57.85 million$61.46 million4/21/2026Q1 2026BBNXBeta Bionics-$0.53-$0.49+$0.04-$0.49N/A$27.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ABBNXBeta BionicsN/AN/AN/AN/AN/ABFLYButterfly NetworkN/AN/AN/AN/AN/ALMATLeMaitre Vascular$1.001.06%+16.05%36.90%14 YearsLatest BBNX, AXGN, BFLY, and LMAT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2026LMATLeMaitre Vascularquarterly$0.251%5/21/20265/21/20266/4/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.087.105.33BBNXBeta BionicsN/A10.699.67BFLYButterfly NetworkN/A4.023.03LMATLeMaitre Vascular0.4214.3212.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%BBNXBeta BionicsN/ABFLYButterfly Network37.85%LMATLeMaitre Vascular84.64%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.44%BBNXBeta Bionics5.30%BFLYButterfly Network21.99%LMATLeMaitre Vascular7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45053.18 million51.88 millionOptionableBBNXBeta Bionics29444.56 million42.20 millionN/ABFLYButterfly Network460254.63 million198.64 millionOptionableLMATLeMaitre Vascular49022.85 million21.16 millionOptionableBBNX, AXGN, BFLY, and LMAT HeadlinesRecent News About These CompaniesLeMaitre Vascular (NASDAQ:LMAT) Lowered to Hold Rating by Wall Street ZenJune 20 at 1:12 AM | americanbankingnews.comLeMaitre Vascular (NASDAQ:LMAT) Rating Lowered to Hold at Wall Street ZenJune 20 at 1:11 AM | marketbeat.comKennedy Capital Management LLC Has $20.11 Million Stock Position in LeMaitre Vascular, Inc. $LMATJune 14, 2026 | marketbeat.comLeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJune 12, 2026 | marketbeat.comLeMaitre Vascular (NASDAQ:LMAT) Shares Cross Above 200 Day Moving Average - Time to Sell?June 11, 2026 | marketbeat.comLeMaitre Vascular Shareholders Back Directors, Pay and AuditorJune 5, 2026 | tipranks.comLeMaitre Vascular (NASDAQ:LMAT) Receives Outperform Rating from Barrington ResearchJune 3, 2026 | marketbeat.comAlphaQuest LLC Grows Position in LeMaitre Vascular, Inc. $LMATMay 27, 2026 | marketbeat.comCasey's & 3 More Stocks With Strong Interest Coverage to Buy NowMay 26, 2026 | zacks.comLeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons WhyMay 25, 2026 | zacks.comLeMaitre to Participate at Upcoming Investor Conferences in JuneMay 20, 2026 | globenewswire.comWinners and losers of Q1: LeMaitre (NASDAQ:LMAT) vs the rest of the surgical equipment & consumables - specialty stocksMay 19, 2026 | msn.comLemaitre Vascular (LMAT) Receives a Buy from SidotiMay 19, 2026 | theglobeandmail.comLemaitre Vascular (LMAT) Gets a Hold from Wells FargoMay 19, 2026 | theglobeandmail.comDown 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a TurnaroundMay 13, 2026 | zacks.comLeMaitre Vascular (NASDAQ:LMAT) Insider Trent Kamke Sells 2,928 SharesMay 12, 2026 | insidertrades.comUS$118 - That's What Analysts Think LeMaitre Vascular, Inc. (NASDAQ:LMAT) Is Worth After These ResultsMay 7, 2026 | finance.yahoo.comLeMaitre to Present at the Bank of America Healthcare ConferenceMay 7, 2026 | globenewswire.com3 Reasons Growth Investors Will Love LeMaitre (LMAT)May 7, 2026 | zacks.comLeMaitre (LMAT) Upgraded to Buy: Here's WhyMay 7, 2026 | zacks.comLMAT Q1 deep dive: Artegraft expansion and pricing drive, margin upside meets cautious marketMay 6, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBNX, AXGN, BFLY, and LMAT Company DescriptionsAxoGen NASDAQ:AXGN$44.84 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$45.16 +0.31 (+0.70%) As of 06/18/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Beta Bionics NASDAQ:BBNX$13.88 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$13.50 -0.38 (-2.74%) As of 06/18/2026 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Butterfly Network NYSE:BFLY$8.85 -0.05 (-0.55%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$9.08 +0.23 (+2.62%) As of 06/18/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging in a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; and Butterfly iQ+ Vet, a handheld ultrasound system designed for veterinarians. The company also provides Butterfly system, which includes probes, and related accessories and software subscriptions to healthcare systems, physicians, and healthcare providers through a direct sales force, distributors, and eCommerce channel. In addition, it offers cloud-based software solutions to healthcare systems, teleguidance, in-app educational tutorials, and formal education programs through its Butterfly Academy software, as well as professional services for large scale deployments; and ScanLab, an education-only app provides written walkthroughs and reference imagery to guide real-time educational scanning, enhancing the learning process. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.LeMaitre Vascular NASDAQ:LMAT$93.95 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$93.90 -0.05 (-0.05%) As of 06/18/2026 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
